Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies

Sponsor
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Study ID
NCT07284927
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • LV009 Injection — BIOLOGICAL
    Eligible subjects who pass the screening process after providing signed informed consent will receive an infusion of LV009 Injection.

Study Details

This clinical trial is designed as a single-arm, open-label, single-center, investigator-initiated, early-phase study. Its primary objective is to evaluate the safety of LV009 Injection in subjects with relapsed/refractory CD19-positive hematolymphoid malignancies.

Key Dates

First listed
Dec 16, 2025
Start date
Dec 3, 2025
Status verified
Dec 2025
Primary completion
Dec 3, 2026
Completion
Dec 3, 2027

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: LV009 Injection

Primary Outcome Measure

Safety [ Time Frame: 2 years ]

Central Contacts

Find similar trials

Nationwide
Leukemia (other) trialsOncology trialsBlood cancer trials

Related Studies